Co-Authors
This is a "connection" page, showing publications co-authored by Massimo Puoti and Antonio Di Biagio.
Connection Strength
0.271
-
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018; 13(2):e0192627.
Score: 0.047
-
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. PLoS One. 2018; 13(1):e0190302.
Score: 0.047
-
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
Score: 0.045
-
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol. 2017 Apr; 40(2):86-98.
Score: 0.044
-
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 04; 37(4):514-528.
Score: 0.044
-
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clin Infect Dis. 2017 03 01; 64(5):680-683.
Score: 0.044